MOTS-c and SS-31 are both called mitochondrial peptides, and the label hides the more interesting distinction. One is encoded by mitochondrial DNA and produced by the organelle. The other is a synthetic tetrapeptide designed to accumulate at a mitochondrial membrane it has no genetic relationship to. Same destination, entirely different origin.
Peptides the mitochondrion writes
Mitochondria carry their own small circular genome, a remnant of the bacterial ancestry of the organelle. For most of the twentieth century that genome was understood to encode a handful of respiratory chain components and the RNA machinery to make them.
The mitochondrial-derived peptides changed that picture. These are short peptides encoded within the mitochondrial genome — humanin was the first described, and MOTS-c became a major research subject after being identified in the 12S rRNA region. The significance is conceptual as much as pharmacological: it means the organelle encodes signalling molecules, not only machinery, and can therefore communicate outward.
Why does the encoding location matter?
Because it implies a signalling direction that was not previously assumed. A peptide encoded in the nucleus and imported to the mitochondrion is the cell instructing the organelle. A peptide encoded by the mitochondrial genome and acting elsewhere in the cell is the reverse — retrograde signalling, the organelle reporting its state outward. That is why MOTS-c attracted the attention it did, and why it is studied in the context of mitochondria-to-nucleus communication rather than as a conventional receptor ligand.
Peptides designed to reach the mitochondrion
SS-31 — also known as elamipretide — is a four-residue synthetic peptide, and its design problem was the opposite one: not where it comes from, but how to get it where it needs to be.
The inner mitochondrial membrane carries a large electrochemical potential, and the peptide's alternating aromatic–cationic structure is what allows it to associate with that membrane and with cardiolipin, a phospholipid largely confined to it. The literature centres on that cardiolipin interaction and its consequences for membrane organisation.
Why is cardiolipin the target rather than a receptor?
Because the mechanism described is structural rather than receptor-mediated. Cardiolipin is unusual — four acyl chains rather than two, and effectively restricted to the inner mitochondrial membrane — and it is involved in organising the protein complexes embedded there. A molecule that binds it is interacting with membrane architecture, which is a different kind of pharmacology from occupying a binding pocket, and it needs different experimental approaches.
Does four residues make SS-31 a simple molecule?
Simple to synthesise and to characterise analytically, yes. Simple in behaviour, no — the property that matters is the alternating charge and aromatic pattern, not the length, and that pattern is what drives the membrane association. Short does not mean trivial here.
| MOTS-c | SS-31 | |
|---|---|---|
| Origin | Encoded in the mitochondrial genome (12S rRNA region) | Synthetic; designed in a laboratory |
| Length | 16 residues | 4 residues |
| Direction of travel | From the mitochondrion outward | From the cytosol into the mitochondrion |
| Proposed target | Signalling in the cytosol and nucleus | Cardiolipin on the inner membrane |
| Receptor | None established | None; binds a lipid, not a protein |
What the grouping is good for, and where it misleads
It is a useful shelf label: these compounds are studied by overlapping communities, in overlapping systems, often alongside metabolic cofactors such as NAD+ — which is not a peptide at all, and handles differently. Reading them together is reasonable.
Where it misleads is mechanism. A mitochondrial-derived peptide and a mitochondria-targeted peptide are not variations on a theme, and an experimental design suited to one may be wrong for the other. MOTS-c research asks what a signal from the organelle does in the wider cell; SS-31 research asks what happens at a specific membrane. Those questions need different controls, different readouts and different systems.
How should either be described in a write-up?
By what it is rather than by the shelf it sits on. "MOTS-c, a mitochondrial-derived peptide encoded in the 12S rRNA region" and "SS-31, a synthetic mitochondria-targeting tetrapeptide" each tell a reader something. "A mitochondrial peptide" tells them almost nothing, and invites the wrong comparison.
Why the mitochondrial genome encodes anything at all
The organelle's genome is tiny — a circular molecule encoding a handful of respiratory subunits plus the tRNAs and rRNAs to translate them. Almost everything else a mitochondrion needs is encoded in the nucleus and imported. That asymmetry is the residue of an ancient endosymbiosis in which most of the bacterial genome migrated to the host nucleus.
Against that background, a peptide encoded within the mitochondrial genome and acting outside the organelle is unexpected, and it is the reason this class attracted the attention it did. It implies the surviving fragment of genome retained, or acquired, a signalling function rather than only a housekeeping one.
Why were these peptides not found earlier?
Because the reading frames are short and sit inside sequences already annotated as something else — MOTS-c is encoded within the 12S rRNA region. Annotation pipelines looking for conventional open reading frames in a genome already characterised as encoding thirteen proteins had no reason to flag them. They were found by looking specifically, not by routine analysis.
Handling considerations the two share
Despite the mechanistic difference, both sit in the same practical bracket: short to moderate sequences, studied in cellular systems, usually at concentrations where adsorption to plasticware is a live concern rather than a theoretical one. Both are worth aliquoting at reconstitution rather than after, and both should be recorded with lot and net peptide content, because cross-study comparison in this area is already difficult without adding avoidable uncertainty about concentration.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
